OCREVUS (ocrelizumab) Patient Assistance Program
Don’t let the high cost of brand anti-CD20 multiple sclerosis biologic disrupt your MS treatment. We help eligible patients access Ocrevus (ocrelizumab intravenous infusion) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Ocrevus (ocrelizumab) is FDA-approved for relapsing forms of MS (clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease) and primary progressive MS (PPMS) in adults — the first and only therapy FDA-approved for PPMS.
- Without assistance, Ocrevus commonly runs approximately $35,000–$45,000 per dose (every 6 months) — roughly $70,000–$90,000 per year.
- Through AffordMyPrescriptions, qualifying patients can access Ocrevus for a flat $69.95 per month while our advocacy team manages the entire enrollment, infusion scheduling, and renewals.
- There is no generic Ocrevus, but Ocrevus Zunovo is a new subcutaneous formulation offering a 10-minute injection alternative to the hours-long IV.
What is Ocrevus Prescription Assistance Program?
The Ocrevus Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Ocrevus (used for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, neurology coordination, hepatitis B and tuberculosis screening documentation, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing chronic neurologic disease.
At AffordMyPrescriptions, our Patient Advocates handle the entire Ocrevus PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your neurologist for required medical documentation (typically including MRI imaging, prior therapy history, HBV and TB screening, and clinical criteria), follow up with the manufacturer’s program until approval, manage your twice-yearly infusion schedule, and handle annual re-certification — so you never face a gap in your Ocrevus MS therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Ocrevus enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your multiple sclerosis treatment.
Pharmacy Price Comparison
- Without assistance, Ocrevus costs tens of thousands of dollars per infusion at MS infusion centers. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this MS biologic accessible if you qualify. The table below compares typical pricing across major settings to what you'd pay with our Ocrevus advocacy service:
| Pharmacy (Setting) | Price (Per Dose)* | You Save W/ Us |
|---|---|---|
| Hospital infusion center | ~$43,000/dose | Save substantially |
| Community infusion center | ~$40,000/dose | Save substantially |
| Specialty pharmacy | ~$37,000/dose | Save substantially |
| 340B-eligible institution | ~$35,000/dose | Save substantially |
| Ocrevus Zunovo SC (alt) | ~$38,000/dose | SC formulation alt |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Ocrevus — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Ocrevus Prescription Program?
The Ocrevus Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Ocrevus is the only FDA-approved therapy for primary progressive MS — twice-yearly dosing offers significant convenience advantage.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Ocrevus assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Ocrevus is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Ocrevus:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $35,000–$45,000 per dose even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Ocrevus assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Ocrevus Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Ocrevus:
Ocrevus (ocrelizumab) is a humanized anti-CD20 monoclonal antibody that selectively depletes CD20-expressing B cells — implicated in MS pathophysiology through antibody production, antigen presentation, and pro-inflammatory cytokine release. It is given as a twice-yearly intravenous infusion after an initial split-dose loading, and is the first and only therapy FDA-approved for primary progressive multiple sclerosis (PPMS) in addition to relapsing forms of MS.
How It Works:
Multiple sclerosis is a chronic autoimmune demyelinating disease of the central nervous system characterized by neuroinflammation, demyelination, and progressive neurodegeneration. B cells contribute through antibody production, antigen presentation to T cells, and pro-inflammatory cytokine release — making B-cell depletion an effective strategy. Ocrelizumab binds CD20 on pre-B and mature B cells (sparing plasma cells and stem cells), depleting them through ADCC and CDC. It dramatically reduces relapses and MRI activity in relapsing MS and was the first therapy to demonstrate efficacy in PPMS.
Form and Use:
Ocrevus is given as an IV infusion. Initial loading is 300 mg IV on day 1, then 300 mg IV on day 15 (split-dose loading). Maintenance is 600 mg IV every 6 months. Each infusion is preceded by IV methylprednisolone 100 mg (or equivalent) and an antihistamine 30–60 minutes beforehand to reduce reactions, with a slow infusion rate. The newer Ocrevus Zunovo subcutaneous formulation offers a roughly 10-minute injection alternative. Periodic CBC, immunoglobulins, and infection monitoring are advised, with HBV and TB screening before initiation.
Generic Availability:
There is no biosimilar or generic Ocrevus. Ocrevus Zunovo is the new subcutaneous formulation, co-formulated with hyaluronidase — a 10-minute SC injection alternative to the hours-long IV, with similar pharmacokinetics and efficacy. Other anti-CD20 MS therapies include Kesimpta (ofatumumab, monthly SC self-injection) and Briumvi (ublituximab, IV every 6 months). Other high-efficacy options include natalizumab (Tysabri), alemtuzumab (Lemtrada), and cladribine (Mavenclad). Moderate-efficacy oral DMTs — many now generic — include fingolimod, siponimod (Mayzent), ozanimod, ponesimod, dimethyl fumarate, diroximel fumarate, monomethyl fumarate, and teriflunomide. Older injectable platform therapies (generic) include interferon-beta products and glatiramer acetate.
Warnings:
Ocrevus carries risks of infusion reactions (especially with the first infusion — premedicate, slow the rate, and monitor) and serious infections (bacterial, viral, and fungal), including hepatitis B reactivation — screen HBsAg, anti-HBc, and anti-HBs before starting, with antiviral prophylaxis if there is exposure history, plus TB screening. Rare cases of PML/JC virus reactivation have been reported. An increased rate of breast cancer was observed in trials, so appropriate cancer screening is advised, and hypogammaglobulinemia can occur with prolonged therapy. Embryo-fetal toxicity is possible, so discuss family planning. Live vaccines are contraindicated during therapy — update vaccines (recombinant zoster, COVID-19, flu, HBV) before starting if possible.
FAQ (Frequently Asked Questions)
How much does Ocrevus cost without insurance?
$35,000–$45,000 per dose (every 6 months), roughly $70,000–$90,000 per year. Specialty pharmacy and Patient Assistance Programs are essential for most patients to access this therapy.
Why is Ocrevus important for primary progressive MS?
Ocrevus is the first and only therapy FDA-approved for primary progressive MS (PPMS), based on the ORATORIO trial — a milestone for a population that historically had no disease-modifying therapy options. PPMS accounts for roughly 10–15% of MS cases and characteristically lacks the relapsing pattern that responds to many DMTs.
What is the difference between Ocrevus and Ocrevus Zunovo?
Same active drug (ocrelizumab). Original Ocrevus is an IV infusion (hours-long). Ocrevus Zunovo is the new subcutaneous formulation, co-formulated with hyaluronidase — a 10-minute SC injection alternative with similar pharmacokinetics and efficacy, substantially reducing chair time and patient burden.
How often do I get Ocrevus infusions?
After initial split-dose loading (two 300 mg doses two weeks apart), the maintenance dose is 600 mg every 6 months. This twice-yearly schedule is a significant convenience advantage. Each infusion takes several hours by IV, or about 10 minutes with Ocrevus Zunovo SC.
What happens if my Ocrevus Patient Assistance Program application is denied?
We help explore Ocrevus Zunovo (SC, same drug), Kesimpta and Briumvi copay programs (other anti-CD20 therapies), natalizumab/Tysabri, Lemtrada and Mavenclad copay, generic oral DMTs (fingolimod, dimethyl fumarate, teriflunomide), generic injectable platform therapies (interferon-beta, glatiramer acetate), the National MS Society MS Navigator program, the MS Foundation, the MS Association of America Patient Assistance program, manufacturer copay programs, the Patient Access Network, Patient Advocate Foundation, NeedyMeds, Medicare Part B/D coverage, and state SPAP programs. If we cannot find a path to access, you are not charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Ocrevus, our team may be able to help you access assistance programs designed to make brand anti-CD20 MS biologic therapy affordable. Check your eligibility today and take the first step toward predictable, sustainable treatment.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.